Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ARE MOOD DISORDERS TREATED BETTER WITH NEW DRUGS
Autore:
JACOBSON NO;
Indirizzi:
CENT HOSP KRISTIANSTAD,DEPT PSYCHIAT S-29185 KRISTIANSTAD SWEDEN
Titolo Testata:
Nordic journal of psychiatry
fascicolo: 3, volume: 49, anno: 1995,
pagine: 199 - 202
SICI:
0803-9488(1995)49:3<199:AMDTBW>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Keywords:
ANTIDEPRESSANT DRUGS; DEPRESSION; MOOD DISORDERS; NATURALISTIC CLINICAL STUDY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Citazioni:
9
Recensione:
Indirizzi per estratti:
Citazione:
N.O. Jacobson, "ARE MOOD DISORDERS TREATED BETTER WITH NEW DRUGS", Nordic journal of psychiatry, 49(3), 1995, pp. 199-202

Abstract

Several new drugs are available for treatment of depression. In Sweden, only older tri- and tetra-cyclic antidepressants (TCAs) were available in 1989. Since then, five new antidepressive drugs (ADs) have beenintroduced: moclobemide, mianserin, and the three selective serotoninreuptake inhibitors (SSRIs) fluvoxamine, paroxetine and citalopram. We studied how old and new ADs were used in our usual clinical setting. The design was simple. The only criterion for inclusion was intentionto treat with an antidepressant drug. During 8 months, from November 1992 until June 1993, 335 such intentions were registered. Later, datawere extracted from the medical records. The main outcome variables were drop-out rate and efficacy of treatment. Global improvement was rated on a four-level scale. Thirty-three patients had 2 or 3 treatment periods, and 260 patients had 1 treatment period each and complete data for follow-up. Main indication was depression in 70% of these cases. Eighty-two per cent of treatments were given with new ADs. Good results were achieved in 48%, and 34% of treatments were stopped because ofside effects or insufficient efficacy. The modest efficacy rate may in part be explained by a great proportion of complicated or treatment-refractory cases. The new ADs did not show better efficacy or less drop-out rate than the old TCAs. There was no significant difference between SSRIs and other drugs. Studies of this kind are important for quality evaluation of new treatments and have a didactic value.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 03:51:04